DXB

5.62%

42.0¢ dimerix limited

Great points mate. Seems there will a hint of efficacy though,...

First 201 Last

Share
Profile

Follow
oilandgasman

1,343 Posts.

102

08/07/17

23:28

Post #: 25749729
Share

Originally posted by Ahmed ↑

Thanks for sharing Prestonian..

1. Agree some ex-Sun Biomedical holders may have sold out since the RTO. The largest SBN holder was Jason Peterson and he recently has sold down his entire holding- which has added to significant supply in recent times.. This is now done.

2. Agree in part that the fact that safety and efficacy hasn't been definitively been demonstrated , given this is the first clinical study, has limited the share price. However, we should keep a few things in mind here- the two compounds are registered and approved drugs! No need to show safety as individual drugs in the dosages used.. This is a huge advantage- better than any other new drug that has shown safety in ph2 or even ph3 trials. The combo mechanistically should be safe, but agree this needs to be shown. Having said that, in my experience the ASX biotech punters don't pay much of a premium for showing safety.. They only want to see efficacy. Also- pls note you won't see any real efficacy in Ph1 studies.

If you look at ACW - it has a market cap of closer to $40M with only phase 1 safety data.. Ph2a just started.. Innate was buoyed by encouraging outcomes with their NZ patients obtaining the drug under compassionate access schemes and positive messaging from the Compamy throughout the study , but that obviously didn't turn out well. PBT really only had safety demonstrated before its ph2b bombed.. Not before a huge rise in the stock price. And then there's little old DXB.. Got a great basis to be safe, has shown in a small sample of 11 patients that it can be extremely effective treating proteinuria in some patients already.. So one would expect it to be trading higher than it is..

So why is the price so low relative to others.. Who knows , maybe..

SBN overhang. Ridiculously low CR at 0.6c in Jan has limited the recent SP gains. Limited broker support. No institutional support (too much for most instos, but wouldn't mind an AEF on board), Lack of strong East Coast support base and awareness. Technology is too complex for most and has until recently been poorly communicated by management. Market value proposition with DMx-200 and CKD /FSGS has been undersold. Business model undersold (licensing opportunities). Overly scientific and conservative approach in communications from the Company to date- much improved now. Other than James Williams- unknown Board. Hugh helps. A decent scientific advisory Board would help too.

Seems like a lot of the above are either being proactively fixed by the Company or are naturally resolving.. So with upcoming results, greater awareness, higher profile board and better corporate messaging- it seems the fun will start after the results rather than before as has been the case with a number of its peers..

All the best guys.. Whatever your strategy is with DXB!

A.

Expand

Great points mate.

Seems there will a hint of efficacy though, given there was with the first set of results.

Why don't instos invest?

DXB Price at posting: 1.1¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

Is oil undervalued?

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GRX

GreenX picks up prospective copper project in Germany

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

WGX

Westgold sets its sights on top five producer status through merger with Karora

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

There are more pages in this discussion • 139 more messages in this thread...

First 201 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 42.0¢		Change -0.025(5.62%)		Mkt cap ! $231.2M

Open	High	Low	Value	Volume
43.5¢	44.0¢	41.8¢	$1.239M	2.905M

Buyers (Bids)

No.	Vol.	Price($)
3	257588	42.0¢

Sellers (Offers)

Price($)	Vol.	No.
42.5¢	10000	1

View Market Depth

No.	Vol.	Price($)
1	9999	0.420
5	140871	0.415
9	112924	0.410
4	97555	0.405
13	124652	0.400

Price($)	Vol.	No.
0.425	10000	1
0.430	107896	3
0.440	20000	1
0.445	100000	1
0.450	83817	4

Last trade - 16.10pm 02/08/2024 (20 minute delay)

DXB (ASX) Chart

Great points mate. Seems there will a hint of efficacy though,...

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Venture to sniff out high-grade REE targets at Jupiter project, WA

Is oil undervalued?

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GreenX picks up prospective copper project in Germany

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Westgold sets its sights on top five producer status through merger with Karora

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Great points mate. Seems there will a hint of efficacy though,...

Top Stories

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Venture to sniff out high-grade REE targets at Jupiter project, WA

Is oil undervalued?

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GreenX picks up prospective copper project in Germany

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Westgold sets its sights on top five producer status through merger with Karora

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News